Grundlæggende statistik
| CIK | 1517681 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Propanc Biopharma, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42806 PROPANC BIOPHARMA, IN |
|
| April 16, 2026 |
April 16, 2026 United States Securities and Exchange Commission Division of Corporation Finance Attn: Tyler Howes 100 F Street, N. |
|
| April 15, 2026 |
April 15, 2026 James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. 302, 6 Butler Street Camberwell, VIC 3124 Australia Re: Propanc Biopharma, Inc. Registration Statement on Form S-1 Filed April 10, 2026 File No. 333-295002 Dear James Nathanielsz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regardin |
|
| April 10, 2026 |
Calculation of Filing Fee Tables S-1 Propanc Biopharma, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Ini |
|
| April 10, 2026 |
As filed with the Securities and Exchange Commission on April 10, 2026 As filed with the Securities and Exchange Commission on April 10, 2026 Registration No. |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Propanc Biopharma, Inc. (Name of Reg |
|
| March 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Propanc Biopharma, Inc. (Name of Reg |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Propanc Biopharma, Inc. (Name of Reg |
|
| March 6, 2026 |
PROPANC BIOPHARMA, INC. 7,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-293147 PROPANC BIOPHARMA, INC. 7,000,000 Shares of Common Stock This prospectus relates to the resale from time to time of up to 7,000,000 shares of our common stock, par value $0.001 per share (“Common Stock”), by the selling stockholder identified herein (the “Selling Stockholder”). The shares of Common Stock being registered hereunder includ |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2026 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-42806 33-0662986 (State or other jurisdiction of Incorporation) (Commissi |
|
| February 26, 2026 |
Exhibit 10.1 DIRECTOR AGREEMENT THIS DIRECTOR AGREEMENT (the “Agreement”) is made effective as of the 20th day of February 2026, and is by and between Propanc Biopharma, Inc., a Delaware corporation (hereinafter referred to as the “Company”), and Dr. Ralf Brandt (hereinafter referred to as the “Director”). WHEREAS, it is essential to the Company to retain and attract as directors the most capable |
|
| February 20, 2026 |
February 20, 2026 United States Securities and Exchange Commission Division of Corporation Finance Attn: Jimmy McNamara 100 F Street, N. |
|
| February 19, 2026 |
As filed with the Securities and Exchange Commission on February 19, 2026 As filed with the Securities and Exchange Commission on February 19, 2026 Registration No. |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42806 PROPANC BIOPHARMA, |
|
| February 12, 2026 |
United States Securities and Exchange Commission United States Securities and Exchange Commission Division of Corporation Finance Attn: Jimmy McNamara 100 F Street, N. |
|
| February 10, 2026 |
February 10, 2026 United States Securities and Exchange Commission Division of Corporation Finance Attn: Jimmy McNamara 100 F Street, N. |
|
| February 10, 2026 |
February 10, 2026 James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. |
|
| February 2, 2026 |
As filed with the Securities and Exchange Commission on February 2, 2026 As filed with the Securities and Exchange Commission on February 2, 2026 Registration No. |
|
| January 30, 2026 |
PROPANC BIOPHARMA, INC. 2,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-292473 PROPANC BIOPHARMA, INC. 2,000,000 Shares of Common Stock This prospectus relates to the resale from time to time of up to 2,000,000 shares of our common stock, par value $0.001 per share (“Common Stock”), by the selling stockholder identified herein (the “Selling Stockholder”). The shares of Common Stock being registered hereunder includ |
|
| January 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-42806 33-0662986 (State or other jurisdiction of Incorporation) (Commissi |
|
| December 30, 2025 |
As filed with the Securities and Exchange Commission on December 29, 2025 As filed with the Securities and Exchange Commission on December 29, 2025 Registration No. |
|
| December 30, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Propanc Biopharma, Inc. |
|
| December 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Propanc Biopharma, Inc. (Name of Reg |
|
| December 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Propanc Biopharma, Inc. (Name of Reg |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-42806 33-0662986 (State or other jurisdiction of Incorporation) (Commissio |
|
| November 10, 2025 |
Exhibit 4.1 CERTIFICATE OF DESIGNATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK OF PROPANC BIOPHARMA, INC. I, James Nathanielsz, hereby certify that I am the Chief Executive Officer of Propanc Biopharma, Inc. (the “Company”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby certify: That pursuant to the authority expressly conferre |
|
| October 14, 2025 |
PROPANC BIOPHARMA, INC. WARRANT TO PURCHASE Series C Preferred stock Exhibit 10.2 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES, (B) THE SALE IS MADE IN ACCORDANCE WITH |
|
| October 14, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 7, 2025, is by and among Propanc Biopharma, Inc., a Delaware corporation with offices located at 302, 6 Butler Street, Camberwell, VIC, 3124, Australia (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collective |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 7, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-42806 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42806 PROPANC BIOPHARMA, INC. (Exact na |
|
| August 19, 2025 |
Exhibit 1.1 UNDERWRITING AGREEMENT between PROPANC BIOPHARMA, INC. And D. BORAL CAPITAL LLC, AS REPRESENTATIVE OF THE UNDERWRITERS TABLE OF CONTENTS Page Section 1. Purchase and Sale of Firm Shares and Over-Allotment Option 3 Section 2. Representations and Warranties of the Company 5 Section 3 Covenants of the Company 18 Section 4 Conditions of Underwriters’ Obligations 25 Section 5 Indemnificatio |
|
| August 19, 2025 |
Exhibit 99.1 Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering Propanc common stock expected to begin trading on Nasdaq under the symbol PPCB Melbourne, Australia / Globe Newswire / August 14, 2025 / Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from r |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-42806 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| August 19, 2025 |
INDEPENDENT DIRECTOR AGREEMENT Exhibit 10.2 INDEPENDENT DIRECTOR AGREEMENT THIS INDEPENDENT DIRECTOR AGREEMENT (this “Agreement”), is made effective as of August 14, 2025, and is by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and the undersigned (the “Director”). RECITALS A. The Company is filing a registration statement on Form S-1 relating to a firm commitment public offering of its securities |
|
| August 19, 2025 |
Exhibit 4.1 Representative’s Warrant THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) D. BORAL CAPITAL LLC, OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE |
|
| August 19, 2025 |
INDEPENDENT DIRECTOR AGREEMENT Exhibit 10.1 INDEPENDENT DIRECTOR AGREEMENT THIS INDEPENDENT DIRECTOR AGREEMENT (this “Agreement”), is made effective as of August 14, 2025, and is by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and the undersigned (the “Director”). RECITALS A. The Company is filing a registration statement on Form S-1 relating to a firm commitment public offering of its securities |
|
| August 19, 2025 |
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ Exhibit 99.2 Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ Melbourne, Australia / Globe Newswire / August 19, 2025 / Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that it closed an underwritten public off |
|
| August 18, 2025 |
PROPANC BIOPHARMA, INC. 3,091,500 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-282886 PROPANC BIOPHARMA, INC. 3,091,500 Shares of Common Stock This prospectus relates to 3,091,500 shares of common stock, par value $0.001 (the “Common Stock”), of Propanc Biopharma, Inc., that may be sold from time to time by the selling stockholders named in this prospectus (the “Selling Stockholders”) following the closing of our uplist t |
|
| August 18, 2025 |
1,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-282886 1,000,000 Shares of Common Stock We are offering 1,000,000 shares of common stock, par value $0.001 (“Common Stock”) of Propanc Biopharma, Inc. (the “Company,” “Propanc,” “we,” “our,” or “us”). We are offering each share of Common Stock at a public offering price of $4.00. There is currently a limited public trading market for our Common |
|
| August 14, 2025 |
The Nasdaq Stock Market LLC, 1100 New York Ave. NW, Suite 310E, Washington, DC 20005 Eun Ah Choi Senior Vice President Global Head of Regulatory Operations August 14, 2025 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporation Finance: This is to certify that on August 13, 2025, The Nasdaq Stock Market (the "Exchang |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission F |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 33-0662986 (State of incorporation or organization) (I.R.S. Employer Identification No.) 302, 6 Butler Street |
|
| August 12, 2025 |
August 12, 2025 United States Securities and Exchange Commission Division of Corporation Finance Attn: Tyler Howes 100 F Street, N. |
|
| August 12, 2025 |
August 12, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 RE: Propanc Biopharma, Inc. Registration Statement on Form S-1, as amended File No. 333- 282886 Concurrence in Acceleration Request Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), D. Bo |
|
| July 31, 2025 |
July 30, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 RE: Propanc Biopharma, Inc. Registration Statement on Form S-1, as amended File No. 333- 282886 Concurrence in Acceleration Request Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), D. Bora |
|
| July 31, 2025 |
July 30, 2025 United States Securities and Exchange Commission Division of Corporation Finance Attn: Tyler Howes 100 F Street, N. |
|
| July 30, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 22, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, A |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission F |
|
| July 30, 2025 |
THE ISSUE PRICE OF THIS NOTE IS $112,350.00 THE ORIGINAL ISSUE DISCOUNT IS $5,350.00 Exhibit 4.1 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE S |
|
| July 29, 2025 |
July 29, 2025 VIA EDGAR CORRESPONDENCE U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Propanc Biopharma, Inc. Registration Statement on Form S-1, as amended File No. 333- 282886 REQUEST FOR WITHDRAWAL OF ACCELERATION OF EFFECTIVENESS Ladies and Gentlemen: Reference is made to our letter, dated July 24, 2025 in which we requeste |
|
| July 29, 2025 |
July 29, 2025 VIA EDGAR CORRESPONDENCE U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Propanc Biopharma, Inc. Registration Statement on Form S-1, as amended File No. 333- 282886 REQUEST FOR WITHDRAWAL OF ACCELERATION OF EFFECTIVENESS Ladies and Gentlemen: Reference is made to our letter, dated July 24, 2025 in which we requeste |
|
| July 28, 2025 |
As filed with the Securities and Exchange Commission on July 28, 2025 As filed with the Securities and Exchange Commission on July 28, 2025 Registration No. |
|
| July 24, 2025 |
July 24, 2025 United States Securities and Exchange Commission Division of Corporation Finance Attn: Tyler Howes 100 F Street, N. |
|
| July 24, 2025 |
July 24, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 RE: Propanc Biopharma, Inc. Registration Statement on Form S-1, as amended File No. 333- 282886 Concurrence in Acceleration Request Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), D. Bora |
|
| July 22, 2025 |
Promissory Note dated July 18, 2025 Exhibit 4.1 PROPANC BIOPHARMA INC. 10% OID Promissory Note DUE September 15, 2025 Original Issue Date: July 18, 2025 Principal Amount: $82,500 Purchase Price: $75,000 FOR VALUE RECEIVED, the undersigned PROPANC BIOPHARMA INC., a Delaware corporation (the “Borrower”), promises to pay to the order of Ionic Ventures, LLC, a California limited liability company, its successors or assigns (the “Lender” |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission F |
|
| June 27, 2025 |
Convertible Promissory Note dated June 13, 2025 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN O |
|
| June 27, 2025 |
Securities Purchase Agreement dated June 13, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 13, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, A |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission F |
|
| June 18, 2025 |
Securities Purchase Agreement dated June 12, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 12, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GEEBIS CONSULTING, LLC, a New Jersey limited liability company, with its address at 812 Avenue N, Brooklyn, N |
|
| June 18, 2025 |
Exhibit 10.2 To: Mr. Josef Zelinger CC: Dr. Julian Kenyon From: Mr. James Nathanielsz Subject: Loan to Propanc Biopharma Inc. – Aggro Investments Pty Ltd Dear Josef Zelinger, The Board of Directors at Propanc Biopharma Inc. (“Propanc”) confirm acceptance and receipt of funds for the sum of thirteen thousand, one hundred and eighty-eight Australian dollars (AU$13,188.00) from Aggro Investments Pty |
|
| June 18, 2025 |
Convertible Promissory Note dated June 12, 2025 Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $25,000 |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission F |
|
| June 2, 2025 |
Promissory Note dated May 30, 2025 Exhibit 4.1 PROPANC BIOPHARMA INC. 10% OID Promissory Note DUE July 15, 2025 Original Issue Date: May 30, 2025 Principal Amount: $60,000 Purchase Price: $50,000 FOR VALUE RECEIVED, the undersigned PROPANC BIOPHARMA INC., a Delaware corporation (the “Borrower”), promises to pay to the order of Ionic Ventures, LLC, a California limited liability company, its successors or assigns (the “Lender”), SIX |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| May 30, 2025 |
Exhibit 1.1 UNDERWRITING AGREEMENT between PROPANC BIOPHARMA, INC. And D. BORAL CAPITAL LLC, AS REPRESENTATIVE OF THE UNDERWRITERS TABLE OF CONTENTS Page Section 1. Purchase and Sale of Firm Shares and Over-Allotment Option 3 Section 2. Representations and Warranties of the Company 5 Section 3 Covenants of the Company 18 Section 4 Conditions of Underwriters’ Obligations 24 Section 5 Indemnificatio |
|
| May 30, 2025 |
As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 Registration No. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA, IN |
|
| May 8, 2025 |
Promissory Note dated May 7, 2025 Exhibit 4.1 PROPANC BIOPHARMA INC. 10% OID Promissory Note DUE June 15, 2025 Original Issue Date: May 7, 2025 Principal Amount: $90,000 Purchase Price: $75,000 FOR VALUE RECEIVED, the undersigned PROPANC BIOPHARMA INC., a Delaware corporation (the “Borrower”), promises to pay to the order of Ionic Ventures, LLC, a California limited liability company, its successors or assigns (the “Lender”), NINT |
|
| May 8, 2025 |
Extension Agreement dated May 7, 2025 Exhibit 10.1 MATURITY EXTENSION AGREEMENT THIS MATURITY EXTENSION AGREEMENT (this “Agreement”), dated as of May 7, 2025 is entered into by and between Propanc Biopharma Inc., a Delaware corporation (the “Company”), and the holder identified on the signature page hereto (the “Holder”). WHEREAS, the Company issued to the Holder two 10% OID Promissory Notes, issued on August 15, 2023 in the original |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| April 25, 2025 |
As filed with the Securities and Exchange Commission on April 25, 2025 As filed with the Securities and Exchange Commission on April 25, 2025 Registration No. |
|
| April 21, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 15, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GS CAPITAL PARTNERS, LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way, Suite |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| April 21, 2025 |
Exhibit 4.2 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN O |
|
| April 21, 2025 |
Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $55,000 |
|
| April 21, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 25, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, |
|
| April 21, 2025 |
Exhibit 10.3 To: Mr. Josef Zelinger CC: Dr. Julian Kenyon From: Mr. James Nathanielsz Subject: Loan to Propanc Biopharma Inc. – Aggro Investments Pty Ltd Dear Josef Zelinger, The Board of Directors at Propanc Biopharma Inc. (“Propanc”) confirm acceptance and receipt of funds for the sum of sixty-three thousand, one hundred and eighty-eight Australian dollars (AU$63,188.00) from Aggro Investments P |
|
| April 8, 2025 |
As filed with the Securities and Exchange Commission on April 8, 2025 As filed with the Securities and Exchange Commission on April 8, 2025 Registration No. |
|
| April 2, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Propanc Biopharma, Inc. |
|
| April 2, 2025 |
Exhibit 99.3 CONSENT OF DIRECTOR NOMINEE In connection with the filing by Propanc Biopharma, Inc. (the “Company”) of a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby consents, as required by R |
|
| April 2, 2025 |
Form of Lock-up Agreement (included in Exhibit 1.1) Exhibit 1.1 UNDERWRITING AGREEMENT between PROPANC BIOPHARMA, INC. and D. BORAL CAPITAL LLC, AS REPRESENTATIVE OF THE UNDERWRITERS TABLE OF CONTENTS Page Section 1. Purchase and Sale of Units and Over-Allotment Option 3 Section 2. Representations and Warranties of the Company 5 Section 3 Covenants of the Company 18 Section 4 Conditions of Underwriters’ Obligations 24 Section 5 Indemnification 27 S |
|
| April 2, 2025 |
As filed with the Securities and Exchange Commission on April 2, 2025 As filed with the Securities and Exchange Commission on April 2, 2025 Registration No. |
|
| April 2, 2025 |
Form of Common Stock Purchase Warrant Exhibit 4.27 COMMON STOCK PURCHASE WARRANT PROPANC BIOPHARMA, INC. Warrant Shares: [●] Initial Exercise Date: [●], 20[●] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the |
|
| April 2, 2025 |
Exhibit 4.28 |
|
| April 2, 2025 |
Exhibit 99.2 CONSENT OF DIRECTOR NOMINEE In connection with the filing by Propanc Biopharma, Inc. (the “Company”) of a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby consents, as required by R |
|
| March 31, 2025 |
Exhibit 10.59 James N athanielsz From: Ralf Brandt Sent: Sun day, 2 February 2025 11:20 AM To: Ralf Brandt Cc: James Nathanielsz Subject: Re: Propanc Biopharma Update Dear James, I’d accept that offer. And I’m looking forward working together Ralf Dear Ralf, My pleasure. Well deserved with hopefully more to come. Let’s call it a sign on fee, acknowledging your recent consultancy work, which has be |
|
| March 31, 2025 |
Exhibit 10.54 From: [email protected] To: James Nathanielsz Subject: RE: Shareholder info Date: Friday, 28 February 2025 6:10:04 AM Attachments: https://www.sec.gov/Archives/edgar/data/1517681/000164117225001355/image001.png James, Thank you very much for the bonus issuance; we greatly appreciate it! As discussed, unless you need them issued individually and separately to each of us, it is probably |
|
| March 31, 2025 |
Exhibit 10.52 CONFIDENTIAL February 18, 2025 James Nathanielsz Propanc Biopharma, Inc. 302/6 Butler Street Camberwell, VIC 3124 Australia 61 3 98826723 Mr. Nathanielsz: Gregory Harrison (“Harrison”) is pleased to act as a non-exclusive business consultant to Propanc Biopharma Inc. (the “Company). This agreement (the “Agreement”) is entered into as of February 18, 2025 (the “Effective Date”), by an |
|
| March 31, 2025 |
Exhibit 10.45 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”) is made and entered into effective as of the 3rd day of March 2025, by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”) and the undersigned holder of warrants of the Company (the “Holder”). W I T N E S S E T H : WHEREAS, the Company created and issued to certain holders, including the Holder, Com |
|
| March 31, 2025 |
Exhibit 10.47 DEBT EXCHANGE AGREEMENT This DEBT EXCHANGE AGREEMENT (this “Agreement”), dated as of January 23, 2025, is entered into by and among Propanc Biopharma Inc., a Delaware corporation (the “Company”) and Dr Doug Mitchell (the “Creditor” and together with the Company, the “Parties” and each, a “Party”). W I T N E S S E T H: WHEREAS, the Company owes the Creditor a total of $74,395 for an o |
|
| March 31, 2025 |
EX-1.1 2 ex1-1.htm Exhibit 1.1 UNDERWRITING AGREEMENT between PROPANC BIOPHARMA, INC. and D. BORAL CAPITAL LLC, AS REPRESENTATIVE OF THE UNDERWRITERS TABLE OF CONTENTS Page Section 1. Purchase and Sale of Units and Over-Allotment Option 3 Section 2. Representations and Warranties of the Company 5 Section 3 Covenants of the Company 18 Section 4 Conditions of Underwriters’ Obligations 24 Section 5 I |
|
| March 31, 2025 |
Exhibit 10.57 CAPITAL MARKET ADVISORY AGREEMENT THIS AGREEMENT, dated as of November 18, 2020, between Propanc Biopharma, Inc. (the “Company”), having its principal place of business at 302, 6 Butler Street, Camberwell VIC 3124 Australia and Exchange Listing, LLC (“Consultant”), having its principal place of business at 1111 S Roop St., Unit 100, Carson City, NV 89702. RECITALS WHEREAS, Consultant |
|
| March 31, 2025 |
Exhibit 99.1 INSIDER TRADING POLICY 1. CONFIDENTIALITY OF INSIDE INFORMATION 1.1 Directors, officers, employees and consultants (“Company Personnel”) of Propanc Health Group Corporation (the “Company”), who come into possession of material non- public information concerning the Company must safeguard the information and not intentionally or inadvertently communicate it to any person (including fam |
|
| March 31, 2025 |
Exhibit 10.49 DEBT EXCHANGE AGREEMENT This DEBT EXCHANGE AGREEMENT (this “Agreement”), dated as of January 28, 2025, is entered into by and among Propanc Biopharma Inc., a Delaware corporation (the “Company”) and Daisy Aronce (the “Creditor” and together with the Company, the “Parties” and each, a “Party”). W I T N E S S E T H: WHEREAS, the Company owes the Creditor a total of $34,500 for SEC Repo |
|
| March 31, 2025 |
Exhibit 10.50 DEBT EXCHANGE AGREEMENT This DEBT EXCHANGE AGREEMENT (this “Agreement”), dated as of January 27, 2025, is entered into by and among Propanc Biopharma Inc., a Delaware corporation (the “Company”) and GrantReady Pty Ltd as trustee for GrantReady Group Trust No1 (the “Creditor” and together with the Company, the “Parties” and each, a “Party”). W I T N E S S E T H: WHEREAS, the Company o |
|
| March 31, 2025 |
Exhibit 10.58 GENERAL SERVICE AGREEMENT THIS GENERAL SERVICE AGREEMENT (the “Agreement”) is dated this10th day of February 10, 2025. CLIENT CONTRACTOR Propanc Biopharma Enzyme Supplies Limited Camberwell Australia John Eccles House, Oxford Science Park (the “Client”) (the “Contractor”) BACKGROUND A. The Client is of the opinion that the Contractor as the necessary qualifications, experience and ab |
|
| March 31, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 31, 2025 |
Exhibit 10.55 CONFIDENTIAL January 9, 2025 James Nathanielsz Propanc Biopharma, Inc. 302/6 Butler Street Camberwell, VIC 3124 Australia 61 3 98826723 Mr. Nathanielsz: Krista Rash (“Rash”) is pleased to act as a non-exclusive traditional IR service provider to Propanc Biopharma Inc. (the “Company). This agreement (the “Agreement”) is entered into as of January 9, 2025 (the “Effective Date”), by and |
|
| March 31, 2025 |
Exhibit 10.51 DEBT EXCHANGE AGREEMENT This DEBT EXCHANGE AGREEMENT (this “Agreement”), dated as of February 05, 2025, is entered into by and among Propanc Biopharma, Inc a Delaware corporation (the “Company”) and Oxfel Pty Ltd (the “Creditor” and together with the Company, the “Parties” and each, a “Party”). WITNESSETH: WHEREAS, the Company owes the Creditor a total of $12,500 for loan (the “Debt” |
|
| March 31, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Propanc Biopharma, Inc. |
|
| March 31, 2025 |
Exhibit 10.42 COMMERCIALIATION Agreement RE PRO-ENZYME TECHNOLOGY This Agreement is entered into on between: (1) PROPANC PTY LTD. a company registered in Australia under number ACN 127 984 098, whose registered office is at Glen Iris, Victoria 3146, Australia (“Propanc”); and (2) UNIVERSITY OF BATH, incorporated by Royal Charter and having an office and place of business at Claverton Down, Bath, B |
|
| March 31, 2025 |
Exhibit 99.2 CONSENT OF DIRECTOR NOMINEE In connection with the filing by Propanc Biopharma, Inc. (the “Company”) of a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby consents, as required by R |
|
| March 31, 2025 |
Exhibit 3.17 |
|
| March 31, 2025 |
Exhibit 10.48 DEBT EXCHANGE AGREEMENT This DEBT EXCHANGE AGREEMENT (this “Agreement”), dated as of February 05, 2025, is entered into by and among Propanc Biopharma, Inc a Delaware corporation (the “Company”) and Notestar Pty Ltd (the “Creditor” and together with the Company, the “Parties” and each, a “Party”). WITNESSETH: WHEREAS, the Company owes the Creditor a total of $63,000 for loan (the “De |
|
| March 31, 2025 |
Exhibit 99.3 CONSENT OF DIRECTOR NOMINEE In connection with the filing by Propanc Biopharma, Inc. (the “Company”) of a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby consents, as required by R |
|
| March 31, 2025 |
Exhibit 10.56 INDEPENDENT CONTRACTORS SERVICES AGREEMENT This Amended Independent Contractor Services Agreement (“Agreement”) is effective as of the 13th day of January 2025, and is by and between Propanc Biopharma, Inc., 302, 6 Butler Street Camberwell, VIC 3124 Australia, Howard Isaacs, (Contractor), 5844 Graves Avenue, Encino, CA 91316, and Richard Cavalli, (Contractor), 3005 NW Craftsman Dr., |
|
| March 31, 2025 |
Exhibit 10.46 DEBT EXCHANGE AGREEMENT This DEBT EXCHANGE AGREEMENT (this “Agreement”), dated as of March 5, 2025 (the “Agreement Date”), is entered into by and between Propane Biopharma, Inc., a Delaware corporation (the “Company”) and Clark Hill PLLC (the “Creditor” and together with the Company, the “Parties” and each, a “Eill:!y”) . WITNESS ETH: WHEREAS, the Company owes the Creditor a total of |
|
| March 31, 2025 |
Exhibit 10.53 CONFIDENTIAL January 9, 2025 James Nathanielsz Propane Biopharma, Inc. 302/6 Butler Street Camberwell, VIC 3124 Australia 61 3 98826723 Mr. Nathanielsz: Ross Silver (“Silver”) is pleased to act as a non-exclusive traditional IR service provider to Propane Biopharma Inc. (the “Company). This agreement (the “Agreement”) is entered into as of January 9, 2025 (the “Effective Date”), by a |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| March 18, 2025 |
Securities Purchase Agreement dated March 11, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 11, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GS CAPITAL PARTNERS, LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way, Suite |
|
| March 18, 2025 |
Convertible Promissory Note dated March 11, 2025 Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $33,000 |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA, |
|
| February 12, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 31, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623 |
|
| February 12, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 7, 2025, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GS CAPITAL PARTNERS, LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way, Suit |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2025 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commissio |
|
| February 12, 2025 |
Convertible Promissory Note dated February 7, 2025 Exhibit 4.2 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $43,000 |
|
| February 12, 2025 |
Convertible Promissory Note dated January 31, 2025 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN O |
|
| December 20, 2024 |
Convertible Promissory Note dated December 4, 2024 Exhibit 4.2 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN O |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commissi |
|
| December 20, 2024 |
Convertible Promissory Note dated December 15, 2024 Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $22,000 |
|
| December 20, 2024 |
Securities Purchase Agreement dated December 15, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 13, 2024, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GEEBIS CONSULTING, LLC, a New Jersey limited liability company, with its address at 812 Avenue N, Brookly |
|
| December 20, 2024 |
Securities Purchase Agreement dated December 4, 2024 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 4, 2024, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and RED ROAD HOLDINGS CORPORATION, a Virginia corporation, with its address at 1765 Duke St., Alexandria, VA 22314 (th |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commissio |
|
| December 6, 2024 |
Loan Agreement with Aggro Investments Pty Ltd dated December 3, 2024. Exhibit 4.1 |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA |
|
| November 6, 2024 |
November 6, 2024 James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. |
|
| October 30, 2024 |
As filed with the Securities and Exchange Commission on October 29, 2024 As filed with the Securities and Exchange Commission on October 29, 2024 Registration Statement No. |
|
| October 30, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Propanc Biopharma, Inc. |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA, INC. (Exact na |
|
| September 27, 2024 |
Securities Purchase Agreement dated September 20, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 20, 2024, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GS CAPITAL PARTNERS, LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way, Su |
|
| September 27, 2024 |
Convertible Promissory Note dated September 20, 2024 Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $33,000 |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commiss |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 26, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Propanc Biopharma, Inc. (Name of Reg |
|
| August 15, 2024 |
Convertible Promissory Note dated August 2, 2024 Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $33,000 |
|
| August 15, 2024 |
Securities Purchase Agreement dated August 2, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 2, 2024, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GS CAPITAL PARTNERS, LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way, Suite |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Propanc Biopharma, Inc. (Name of Reg |
|
| August 7, 2024 |
Loan Agreement dated June 3, 2024 Exhibit 4.1 Biopharma, Inc. To: Mr. Josef Zelinger CC: Dr. Julian Kenyon From: Mr. James Nathanielsz Subject: Loan to Propane Biopharma Inc. - Joshua Investments Pty Ltd Dear Josef Zelinger, The Board of Directors at Propane Biopharma Inc. (‘‘Propane’’) confirm acceptance and receipt of funds for the sum of one hundred and fifty thousand Australian dollars (AUD 150,000) from Joshua Investments Pty |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission F |
|
| July 2, 2024 |
Securities Purchase Agreement dated June 20, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 20, 2024, by and between Propanc Biopharma, Inc., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124, Australia (the “Company”), and 104 LLC, a Nevada limited liability company, with its address at 21520 Yorba Linda Blvd., Suite G PMB 335, Y |
|
| July 2, 2024 |
Convertible Promissory Note dated June 20, 2024 Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| June 21, 2024 |
Securities Purchase Agreement dated June 10, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 10, 2024, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, A |
|
| June 21, 2024 |
Convertible Promissory Note dated June 10, 2024 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN O |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission F |
|
| June 13, 2024 |
Loan Agreement dated June 3, 2024 Exhibit 4.1 To: Dr Nick Loizou / Susan Loizou CC: Mr. Josef Zelinger From: Mr. James Nathanielsz Subject: Loan to Propanc Biopharma Inc. Dear Susan Loizou, The Board of Directors at Propanc Blopharma Inc. (“Propanc”) confirm acceptance and receipt of funds for the sum of twenty thousand Australian dollars (AUD 20,000) from Susan Loizou (the “Lender”) of 40 Highland Road, Keilor, Vic 3036 (“address |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| June 13, 2024 |
Loan Agreement dated June 5, 2024 Exhibit 4.2 To: Mr. Paul Mazor CC: Mr. Josef Zelinger From: Mr. James Nathanielsz Subject: Loan to Propanc Biopharma Inc. Dear Mr. Mazor, The Board of Directors at Propanc Biopharma Inc. (“Propanc’’) confirm acceptance and receipt of funds for the sum of one hundred thousand Australian dollars (AUD 100,000) from Paul Mazor (the “lender’’) of Apt 2903, 389/1413 The Peak Towers, M. Kasetsin 9 Rd. No |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| June 12, 2024 |
Loan Agreement dated June 3, 2024 Exhibit 4.1 To: Dr Nick Loizou / Susan Loizou CC: Mr. Josef Zelinger From: Mr. James Nathanielsz Subject: Loan to Propane Biopharma Inc. Dear Susan Loizou, The Board of Directors at Propane Blopharma Inc. (“Propane”) confirm acceptance and receipt of funds for the sum of twenty thousand Australian dollars (AUD 20,000) from Susan Loizou (the “Lender”) of 40 Highland Road, Keilor, Vic 3036 (“address |
|
| June 12, 2024 |
Loan Agreement dated June 5, 2024 Exhibit 4.2 To: Mr. Paul Mazor CC: Mr. Josef Zelinger From: Mr. James Nathanielsz Subject: Loan to Propane Biopharma Inc. Dear Mr. Mazor, The Board of Directors at Propane Biopharma Inc. (“Propane’’) confirm acceptance and receipt of funds for the sum of one hundred thousand Australian dollars (AUD 100,000) from Paul Mazor (the “lender’’) of Apt 2903, 389/1413 The Peak Towers, M. Kasetsin 9 Rd. No |
|
| June 5, 2024 |
Securities Purchase Agreement dated May 22, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 22, 2024, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, Al |
|
| June 5, 2024 |
Convertible Promissory Note dated May 22, 2024 Exhibit 4.1 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN O |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission Fi |
|
| May 16, 2024 |
Maturity Extension Agreement dated May 10, 2024 Exhibit 10.1 MATURITY EXTENSION AGREEMENT THIS MATURITY EXTENSION AGREEMENT (this “Agreement”), dated as of May 10, 2024 is entered into by and between Propanc Biopharma Inc., a Delaware corporation (the “Company”), and the holder identified on the signature page hereto (the “Holder”). WHEREAS, the Company issued to the Holder a 10% OID Promissory Note, issued on August 15, 2023 in the original pr |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA, IN |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| April 22, 2024 |
Convertible Promissory Note dated April 12, 2024 Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $27,500 |
|
| April 22, 2024 |
Securities Purchase Agreement dated April 12, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 12, 2024, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GS CAPITAL PARTNERS, LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way, Suite |
|
| April 10, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission |
|
| April 10, 2024 |
Propanc Biopharma, Inc. corporate overview and presentation Exhibit 99.1 |
|
| March 11, 2024 |
Convertible Promissory Note dated March 1, 2024 Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| March 11, 2024 |
Securities Purchase Agreement dated March 1, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 1, 2024, by and between Propanc Biopharma, Inc., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124, Australia (the “Company”), and 104 LLC, a Nevada limited liability company, with its address at 21520 Yorba Linda Blvd., Suite G PMB 335, Y |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2024 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commission F |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA, |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54878 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Tran |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2023 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commissi |
|
| December 15, 2023 |
Convertible Promissory Note dated December 8, 2023 Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $150,00 |
|
| December 15, 2023 |
Securities Purchase Agreement dated December 8, 2023 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 8, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and ONE44 CAPITAL LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way Suite 202, R |
|
| December 7, 2023 |
Securities Purchase Agreement dated November 29, 2023 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 29, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 62 |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2023 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commissio |
|
| December 7, 2023 |
Convertible Promissory Note dated November 29, 2023 Exhibit 4.1 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE S |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2023 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) (Commissio |
|
| October 26, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 20, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623 |
|
| October 26, 2023 |
8% Convertible Promissory Note, dated October 20, 2023, issued to the Investor. Exhibit 4.1 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE S |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2023 (October 20, 2023) PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorp |
|
| October 17, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 12, 2023 by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GS CAPITAL PARTNERS, LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way, Suite |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2023 (October 12, 2023) PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorp |
|
| October 17, 2023 |
8% Convertible Redeemable Note, dated October 12, 2023, issued to the Investor Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $61,000 |
|
| October 17, 2023 |
Propanc Biopharma, Inc. Up to 26,250,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-273953 PROSPECTUS Propanc Biopharma, Inc. Up to 26,250,000 Shares of Common Stock This prospectus relates to the offer and resale, from time to time, of up to 26,250,000 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of Propanc Biopharma, Inc. (the “Company,” “we,” “our” and “us”) by Dutchess Capital Gro |
|
| October 10, 2023 |
As filed with the U.S. Securities and Exchange Commission on October 10, 2023 As filed with the U.S. Securities and Exchange Commission on October 10, 2023 Registration No. 333-273953 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 33-0662986 (State or other jurisdiction of in |
|
| October 10, 2023 |
Propanc Biopharma, Inc. 302, 6 Butler Street Camberwell, VIC 3124 Propanc Biopharma, Inc. 302, 6 Butler Street Camberwell, VIC 3124 Australia October 10, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Re: Propanc Biopharma, Inc. Registration Statement on Form S-1, as amended File No. 333-273953 Ladies and Gentlemen: Propanc Biopharma, Inc. (the “Company”) hereby requests acce |
|
| October 6, 2023 |
As filed with the U.S. Securities and Exchange Commission on October 6, 2023 As filed with the U.S. Securities and Exchange Commission on October 6, 2023 Registration No. 333-273953 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 33-0662986 (State or other jurisdiction of inc |
|
| September 28, 2023 |
Exhibit 21.1 Propanc Biopharma, Inc. List of Subsidiaries As of September 28, 2023 Entity Name Propanc Pty Ltd Propanc (UK) Ltd |
|
| September 28, 2023 |
Exhibit 14.1 Propane Health Group Corporation Code of Ethics Introduction These Ethical Guidelines will serve as the Code of Ethics (“Guidelines”) for Propanc Health Group Corporation (“Propane”) and as such they cover a wide spectrum of business practices and procedures. They do not cover every issue that may arise, but they set out some basic principles to guide all employees and directors of Pr |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA, INC. (Exact na |
|
| August 29, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 23, 2023 by and between PROPANC BIOPHARMA, INC,, a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and GS CAPITAL PARTNERS, LLC, a Nevada limited liability company, with its address at 1325 Airmotive Way, Suite |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2023 (August 23, 2023) PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorpor |
|
| August 29, 2023 |
Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $77,500 |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2023 (August 15, 2023) PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorpor |
|
| August 21, 2023 |
Exhibit 4.1 PROPANC BIOPHARMA INC. 10% OID PROMISSORY NOTE DUE NOVEMBER 15, 2023 Original Issue Date: August 15, 2023 Principal Amount: $132,000 Purchase Price: [$120,000] FOR VALUE RECEIVED, the undersigned PROPANC BIOPHARMA INC., a Delaware corporation (the “Borrower”), promises to pay to the order of IONIC VENTURES, LLC, a California limited liability company, its successors or assigns (the “Le |
|
| August 21, 2023 |
Exhibit 4.2 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE S |
|
| August 21, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 16, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, |
|
| August 15, 2023 |
United States securities and exchange commission logo August 15, 2023 James Nathanielsz Chief Executive Officer Propanc Biopharma, Inc. |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Propanc Biopharma, Inc. |
|
| August 11, 2023 |
As filed with the U.S. Securities and Exchange Commission on August 11, 2023 As filed with the U.S. Securities and Exchange Commission on August 11, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 33-0662986 (State or other jurisdiction of incorporation or organizatio |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2023 (July 19, 2023) PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporati |
|
| August 8, 2023 |
Exhibit 4.1 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE S |
|
| August 8, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July 19, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, A |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 (July 20, 2023) PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporatio |
|
| July 26, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 20, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and DUTCHESS CAPITAL GROWTH FUND L.P., a Delaware limited partnership (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have th |
|
| July 26, 2023 |
Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement is entered into as of July 20, 2023 (this “Agreement”), by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and DUTCHESS CAPITAL GROWTH FUND L.P., a Delaware limited partnership (the “Investor”). The Company and Investor may be referred to herein as each a “Party” and, collectively, the “P |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2023 (July 12, 2023) PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporatio |
|
| July 12, 2023 |
Exhibit 4.2 1 2 3 4 5 6 7 8 9 10 11 |
|
| July 12, 2023 |
Exhibit 10.2 To: Mr. Josef Zelinger CC: Dr Julian Kenyon From: Mr. James Nathanielsz Subject: Company Loan from Aggro Investments Pty Ltd to Propanc Biopharma Inc. Dear Mr Zelinger, The Board of Directors at Propanc Biopharma Inc. (“Propanc”) confirm acceptance and receipt of funds for the sum of two hundred and thirty thousand Australian dollars (AUD 230,000) from Aggro Investments Pty Ltd (“Aggr |
|
| July 12, 2023 |
Exhibit 4.1 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE S |
|
| July 12, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 29, 2023, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, A |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA, IN |
|
| May 15, 2023 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”), dated as of November 3, 2022, by and between PROPANC BIOPHARMA, INC., a Delaware corporation (the “Company”), and Coventry Enterprises, LLC, a Delaware limited liability company (together with it permitted assigns, the “Investor”) (the Company and Investor each a “Party” and together the “Parties”). C |
|
| May 15, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 3, 2022 between Propanc Biopharma, Inc. a Delaware corporation (the “Company”), and Coventry Enterprises, LLC, a Delaware limited liability company (“Investor”). WITNESSETH WHEREAS, the Company and the Investor are executing and delivering this Agreement in reliance upon an exempt |
|
| May 15, 2023 |
Exhibit 10.2 COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”) is entered into as of November 3, 2022, by and between PROPANC BIOPHARMA INC., a Delaware corporation (the “Company”), and COVENTRY ENTERPRISES, LLC, a Delaware limited liability company (the “Investor”). The Company and Investor may be referred to herein as each a ‘‘Party” and collectively, the “Pa |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 (November 3, 2022) PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporat |
|
| May 15, 2023 |
Exhibit 10.4 PROPANC BIOPHARMA, INC. March 8, 2023 Holder of Series B Common Stock Purchase Warrants Regarding: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Propanc Biopharma, Inc. (the “Company”) is pleased to accept your offer to exercise up to $250,000 of Series B Warrants Common Stock Purchase Warrants (the “Existing Warrants”) currently held by you (“you”), as foll |
|
| May 15, 2023 |
Note, dated November 3, 2022, issued to the Investor Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES THAT MAY BE CONVERTED (SOLELY UPON AN EVENT OF DEFAULT IN THE ISSUER’S REPAYMENT OBLIGATIONS HEREUNDER) HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, M |
|
| May 5, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF PROPANC BIOPHARMA, INC. Propanc Biopharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: FIRST: The name of the Corporation is Propanc Biopharma, Inc. SECOND: This certificate of amendment (this “Certificate |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2023 (May 1, 2023) PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of Incorporation) ( |
|
| April 4, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-238240 PROSPECTUS Propanc Biopharma, Inc. 23,750 Shares of Common Stock Issuable Upon Exercise of Outstanding Series B Warrants This prospectus relates to the issuance of up to 23,750 shares of Common Stock underlying warrants (the “Series B Warrant”) currently outstanding. Each Series B Warrant has an exercise price per share equal to $40.00 p |
|
| March 24, 2023 |
Exhibit 10.55 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 3, 2022 between Propanc Biopharma, Inc. a Delaware corporation (the “Company”), and Coventry Enterprises, LLC, a Delaware limited liability company (“Investor”). WITNESSETH WHEREAS, the Company and the Investor are executing and delivering this Agreement in reliance upon an exemp |
|
| March 24, 2023 |
Exhibit 10.56 COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”) is entered into as of November 3, 2022, by and between PROPANC BIOPHARMA INC., a Delaware corporation (the “Company”), and COVENTRY ENTERPRISES, LLC, a Delaware limited liability company (the “Investor”). The Company and Investor may be referred to herein as each a ‘‘Party” and collectively, the “P |
|
| March 24, 2023 |
As filed with the Securities and Exchange Commission on March 24, 2023 As filed with the Securities and Exchange Commission on March 24, 2023 Registration No. |
|
| March 24, 2023 |
10% Promissory Note, dated November 3, 2022, issued by the Company to Coventry Enterprises, LLC Exhibit 4.21 NEITHER THIS SECURITY NOR THE SECURITIES THAT MAY BE CONVERTED (SOLELY UPON AN EVENT OF DEFAULT IN THE ISSUER’S REPAYMENT OBLIGATIONS HEREUNDER) HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2023 |
Exhibit 3.15 |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of incorporation) (Commissi |
|
| February 21, 2023 |
Exhibit 10.41 |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of incorporation) (Commissi |
|
| February 21, 2023 |
Exhibit 4.20 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $111,1 |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA, |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of incorporation) (Commissio |
|
| November 1, 2022 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this“Agreement”) dated October 26, 2022, is made effective as of July 1, 2022 (the “Effective Date”) by and between Propanc Biopharma, Inc., a Delaware corporation (the “Company”), and James Nathanielsz (“Executive”). The Company and Executive sometimes are referred to herein collectively as the |
|
| October 12, 2022 |
Exhibit 4.1 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE S |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of incorporation) (Commission |
|
| October 12, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of October 6, 2022, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the ?Company?), and Red Road Holdings Corporation, a Virginia corporation, with its address at 1765 Duke St, Alexandria, VA 22314 (the |
|
| October 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement PROPANC BIOPHARMA, INC. |
|
| September 28, 2022 |
Exhibit 21.1 Propanc Biopharma, Inc. List of Subsidiaries As of September 28, 2022 Entity Name Propanc Pty Ltd Propanc (UK) Ltd |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54878 PROPANC BIOPHARMA, INC. (Exact na |
|
| September 27, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of September 21, 2022, by and between PROPANC BIOPHARMA, INC,, a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the ?Company?), and GS CAPITAL PARNTERS, LLC, a Nevada limited liability company, with its address at 1 East Liberty Street, |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of incorporation) (Commiss |
|
| September 27, 2022 |
Exhibit 4.1 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $71,500 |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement PROPANC BIOPHARMA, INC. |
|
| August 18, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of August 12, 2022, by and between PROPANC BIOPHARMA, INC,, a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the ?Company?), and GS CAPITAL PARNTERS, LLC, a Nevada limited liability company, with its address at 1 East Liberty Street, Su |
|
| August 18, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of August 15, 2022, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the ?Company?), and ONE44 CAPITAL LLC, a Nevada limited liability company, with its address at 1 East Liberty Street Suite 600, |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 PROPANC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54878 33-0662986 (State or other jurisdiction of incorporation) (Commission |
|
| August 18, 2022 |
Exhibit 4.2 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $110,00 |
